Clinical Trials Logo

Neuroendocrine Tumors clinical trials

View clinical trials related to Neuroendocrine Tumors.

Filter by:

NCT ID: NCT00137774 Completed - Clinical trials for Neuroendocrine Tumors

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Start date: November 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.

NCT ID: NCT00131911 Completed - Clinical trials for Neuroendocrine Tumor

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00093782 Completed - Clinical trials for Metastatic Gastrointestinal Carcinoid Tumor

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Start date: December 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00088595 Completed - Carcinoid Tumors Clinical Trials

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Start date: January 2004
Phase: Phase 2
Study type: Interventional

Study evaluating SOM230 in patients with metastatic carcinoid tumors

NCT ID: NCT00075439 Completed - Insulinoma Clinical Trials

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Start date: December 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

NCT ID: NCT00056693 Completed - Clinical trials for Neuroendocrine Tumors

Treatment With SU11248 in Patients With Neuroendocrine Tumors

Start date: April 2003
Phase: Phase 2
Study type: Interventional

To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.

NCT ID: NCT00055809 Completed - Clinical trials for Metastatic Gastrointestinal Carcinoid Tumor

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Start date: January 2003
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PEG-interferon alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. Combining bevacizumab with PEG-interferon alfa-2b may kill more cancer cells

NCT ID: NCT00050349 Completed - Clinical trials for Neuroendocrine Tumors

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Start date: July 2002
Phase: Phase 2
Study type: Interventional

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid and other neuroendocrine tumors.

NCT ID: NCT00049023 Completed - Sarcoma Clinical Trials

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Start date: January 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. PURPOSE: This phase I trial is to study the safety and effectiveness of radiolabeled octreotide in treating children who have advanced or refractory solid tumors.

NCT ID: NCT00037869 Completed - Clinical trials for Neuroendocrine Tumors

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

Start date: November 2001
Phase: Phase 3
Study type: Interventional

The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine (MIBG) can shrink or slow the growth of the tumor(s) in patients with metastatic neuroendocrine tumors. The safety of this treatment will also be studied.